The promise of genetic testing helping to reduce the occurrence of adverse events in high-risk patients, with the help of a clinical decision tool, has been realized in a small study recently reviewed by Healthcare IT Analytics.
The study, originally published in PLOS ONE, was conducted by researchers studying drug-drug and drug-gene interactions with patients who had a high risk of adverse drug effects. The results included a reported 85% reduced risk of death and an estimated cost savings of $4,382 per capita. Patients' individual genetic responses to medication account for nearly half of the instances that result in adverse drug reactions, cited the study.
With one or more prescription drugs being used daily by adults over 65, adverse events remain as one of the most costly risks (physically and monetarily) to seniors, 35 percent of which will experience an ADE (Health IT Analytics). "Preventable readmissions cost Medicare around $17 billion per year."
Please reference the article below for more on this study.